Fig. 8From: Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitorsDuration until resistance acquisition under reversible and irreversible EGFR TKI therapy. Median PFS until resistance acquisition under reversible (first generation EGFR TKI erlotinib and gefitinib) an irreversible EGFR TKI (afatinib) therapy. Statistical significance is indicated by p = 0.003 (determined by student’s t-test)Back to article page